Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Indolent Lymphoproliferative Disorders”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Study completedNCT01219010
What this trial is testing

A Study Evaluating the Effects of Siltuximab on the Heart in Patients With Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma, or Indolent Multiple Myeloma

Who this might be right for
Monoclonal Gammopathy of Undetermined SignificanceMultiple MyelomaPlasma Cell Neoplasm
Janssen Research & Development, LLC 30
Testing effectiveness (Phase 2)Study completedNCT01929265
What this trial is testing

A Phase II Study for Patients With Indolent Non-follicular Non-Hodgkin's Lymphoma

Who this might be right for
Indolent Non-follicularNon-Hodgkin's Lymphoma
Fondazione Italiana Linfomi - ETS 73
Early research (Phase 1)Active Not RecruitingNCT04464200
What this trial is testing

19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers

Who this might be right for
Diffuse Large B Cell LymphomaPrimary Mediastinal Large B Cell LymphomaTransformed Follicular Lymphoma to Diffuse Large B Cell Lymphoma+6 more
Memorial Sloan Kettering Cancer Center 30
Testing effectiveness (Phase 2)Study completedNCT02342665
What this trial is testing

Japanese Phase Ib/II Copanlisib in Relapsed, Indolent B-cell NHL

Who this might be right for
Lymphoma Non-Hodgkin
Bayer 25
Testing effectiveness (Phase 2)Study completedNCT01994382
What this trial is testing

Phase 1/2a Dose Escalation Study in Participants With CLL, SLL, or NHL

Who this might be right for
Follicular Lymphoma (FL/Indolent NHL)Aggressive NHL (a NHL)Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL)+2 more
Alexion Pharmaceuticals, Inc. 260
Testing effectiveness (Phase 2)Study completedNCT00093769
What this trial is testing

Bortezomib and Rituximab in Treating Patients With Non-Hodgkin's Lymphoma

Who this might be right for
Lymphoma
Jonsson Comprehensive Cancer Center 15
Large-scale testing (Phase 3)Study completedNCT01596621
What this trial is testing

Bendamustine in the Treatment of Chinese Participants With Indolent Non-Hodgkin Lymphoma Refractory to Rituximab Treatment

Who this might be right for
Non-Hodgkin Lymphoma
Teva Branded Pharmaceutical Products R&D, Inc. 102
Large-scale testing (Phase 3)Study completedNCT01231412
What this trial is testing

Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant

Who this might be right for
Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaAggressive Non-Hodgkin Lymphoma+16 more
Fred Hutchinson Cancer Center 174
Early research (Phase 1)Study completedNCT04578600
What this trial is testing

CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma

Who this might be right for
Indolent B-Cell Non-Hodgkin LymphomaRecurrent B-Cell Non-Hodgkin LymphomaRecurrent Chronic Lymphocytic Leukemia+16 more
Joseph Tuscano 8
Early research (Phase 1)Study completedNCT04599634
What this trial is testing

Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies

Who this might be right for
Follicular LymphomaMarginal Zone LymphomaMantle Cell Lymphoma+2 more
National Cancer Institute (NCI) 11
Testing effectiveness (Phase 2)Active Not RecruitingNCT05458297
What this trial is testing

Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)

Who this might be right for
Chronic Lymphocytic LeukemiaMantle Cell LymphomaFollicular Lymphoma+1 more
Merck Sharp & Dohme LLC 189
Testing effectiveness (Phase 2)Looking for participantsNCT05635162
What this trial is testing

Zanubrutinib Plus Rituximab for Patients With Indolent Mantle Cell Lymphoma

Who this might be right for
Mantle Cell Lymphoma
University College, London 50
Early research (Phase 1)Study completedNCT00052416
What this trial is testing

Thalidomide in Treating Patients With Asymptomatic, Indolent Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

Who this might be right for
LeukemiaLymphoma
Beth Israel Deaconess Medical Center
Testing effectiveness (Phase 2)Ended earlyNCT01944943
What this trial is testing

Phase II Study of Vismodegib in Patients With Refractory or Relapsed B-cell Lymphoma or Chronic Lymphocytic Leukemia

Who this might be right for
Diffuse Large B-cell LymphomaIndolent Non-hodgkin LymphomaPrimary Central Nervous System Lymphoma+1 more
The Lymphoma Academic Research Organisation 31
Testing effectiveness (Phase 2)Temporarily pausedNCT07098364
What this trial is testing

ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in Relapsed/Refractory Large B-Cell Lymphoma

Who this might be right for
Recurrent Diffuse Large B-Cell LymphomaRecurrent Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedRecurrent Grade 3b Follicular Lymphoma+9 more
Fred Hutchinson Cancer Center 33
Testing effectiveness (Phase 2)Study completedNCT05169658
What this trial is testing

Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin Lymphoma

Who this might be right for
Non-Hodgkin LymphomaGrade 1 Follicular LymphomaGrade 2 Follicular Lymphoma+5 more
University of Washington 42
Testing effectiveness (Phase 2)Study completedNCT00087425
What this trial is testing

Bryostatin 1 and Rituximab in Treating Patients With B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

Who this might be right for
LeukemiaLymphoma
National Institute on Aging (NIA) 48
Early research (Phase 1)Looking for participantsNCT05418088
What this trial is testing

Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies

Who this might be right for
Recurrent Acute Lymphoblastic LeukemiaRecurrent B Acute Lymphoblastic LeukemiaRecurrent B-Cell Prolymphocytic Leukemia+15 more
Sumithira Vasu 54
Testing effectiveness (Phase 2)Ended earlyNCT01316523
What this trial is testing

Lenalidomide and Rituximab in Subjects With Previously Untreated Indolent Non-Hodgkin's Lymphoma

Who this might be right for
Non Hodgkin's Lymphoma
University of California, Davis 30
Early research (Phase 1)Active Not RecruitingNCT07166419
What this trial is testing

Anti-CD19/20/22 Chimeric Antigen Receptor T Cells (TriCAR19.20.22 T Cells) for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, and Chronic Lymphocytic Leukemia

Who this might be right for
Blast Phase Chronic Myeloid Leukemia, BCR-ABL1 PositiveRecurrent Acute Lymphoblastic LeukemiaRecurrent Chronic Lymphocytic Leukemia+12 more
Ohio State University Comprehensive Cancer Center
Next Page
24